logo-loader

Hedge Fund Ramius ratchets up the pressure on Cypress Bioscience with hostile offer

Published: 04:57 16 Sep 2010 AEST

no_picture_pai

Cypress Bioscience, Inc (NASDAQ:CYPB) jumped nearly 10% in early deals after Hedge Fund Ramius LLC announced a hostile takeover offer of US$4.25 per share (approximately US$163 million).


Ramius offered $4.00 per shares in July, which valued the company at approximately US$150  million, but had failed to secure the support of the company`s board for the offer.  This morning, Cypress confirmed that Ramius had increased its offer and would be taking it directly to the company`s shareholders.


Cypress Bioscience is a pharmaceutical company with a number of products, including Prosorba, a medical device for rheumatoid arthritis, and Savella, for fibromyalgia.


The tender offer expires October 13th and is conditional on a number of factors, including tender support being 90% of shares.  Ramius already holds around 10% of Cypress Bioscience`s equity.


Cypress has previously rejected Ramius's approaches, saying they undervalue the company.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

1 hour, 31 minutes ago